Search Results - "Brashear, Robert H."

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease by Salloway, Stephen, Sperling, Reisa, Fox, Nick C, Blennow, Kaj, Klunk, William, Raskind, Murray, Sabbagh, Marwan, Honig, Lawrence S, Porsteinsson, Anton P, Ferris, Steven, Reichert, Marcel, Ketter, Nzeera, Nejadnik, Bijan, Guenzler, Volkmar, Miloslavsky, Maja, Wang, Daniel, Lu, Yuan, Lull, Julia, Tudor, Iulia Cristina, Liu, Enchi, Grundman, Michael, Yuen, Eric, Black, Ronald, Brashear, H. Robert

“…In two phase 3 trials in patients with Alzheimer's disease, bapineuzumab, a humanized anti–amyloid-beta monoclonal antibody, did not improve clinical outcomes…”
Get full text

Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis by Sperling, Reisa, Dr, Salloway, Stephen, Prof, Brooks, David J, Prof, Tampieri, Donatella, MD, Barakos, Jerome, MD, Fox, Nick C, Prof, Raskind, Murray, Prof, Sabbagh, Marwan, MD, Honig, Lawrence S, MD, Porsteinsson, Anton P, Prof, Lieberburg, Ivan, MD, Arrighi, H Michael, PhD, Morris, Kristen A, MS, Lu, Yuan, MS, Liu, Enchi, PhD, Gregg, Keith M, PhD, Brashear, H Robert, MD, Kinney, Gene G, PhD, Black, Ronald, MD, Grundman, Michael, MD

“…Summary Background Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheimer's disease treated with bapineuzumab, a humanised…”
Get full text

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study by Novak, Gerald, Streffer, Johannes Rolf, Timmers, Maarten, Henley, David, Brashear, H Robert, Bogert, Jennifer, Russu, Alberto, Janssens, Luc, Tesseur, Ina, Tritsmans, Luc, Van Nueten, Luc, Engelborghs, Sebastiaan

“…Atabecestat, a potent brain-penetrable inhibitor of BACE1 activity that reduces CSF amyloid beta (Aβ), was developed for oral treatment for Alzheimer's disease…”
Get full text

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials by Vandenberghe, Rik, Rinne, Juha O, Boada, Mercè, Katayama, Sadao, Scheltens, Philip, Vellas, Bruno, Tuchman, Michael, Gass, Achim, Fiebach, Jochen B, Hill, Derek, Lobello, Kasia, Li, David, McRae, Tom, Lucas, Prisca, Evans, Iona, Booth, Kevin, Luscan, Gerald, Wyman, Bradley T, Hua, Lisa, Yang, Lingfeng, Brashear, H Robert, Black, Ronald S

“…Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer's…”
Get full text

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup by Sperling, Reisa A, Jack, Clifford R, Black, Sandra E, Frosch, Matthew P, Greenberg, Steven M, Hyman, Bradley T, Scheltens, Philip, Carrillo, Maria C, Thies, William, Bednar, Martin M, Black, Ronald S, Brashear, H. Robert, Grundman, Michael, Siemers, Eric R, Feldman, Howard H, Schindler, Rachel J

“…Abstract Amyloid imaging related abnormalities (ARIA) have now been reported in clinical trials with multiple therapeutic avenues to lower amyloid-β burden in…”
Get full text

Designing drug trials for Alzheimer’s disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force by Vellas, Bruno, Carrillo, Maria C, Sampaio, Cristina, Brashear, H. Robert, Siemers, Eric, Hampel, Harald, Schneider, Lon S, Weiner, Michael, Doody, Rachelle, Khachaturian, Zaven, Cedarbaum, Jesse, Grundman, Michael, Broich, Karl, Giacobini, Ezio, Dubois, Bruno, Sperling, Reisa, Wilcock, Gordon K, Fox, Nick, Scheltens, Philip, Touchon, Jacques, Hendrix, Suzanne, Andrieu, Sandrine, Aisen, Paul

“…Abstract An international task force of investigators from academia, industry, nonprofit foundations, and regulatory agencies met in Monte Carlo, Monaco, on…”
Get full text

The pathway to secondary prevention of Alzheimer's disease by McDade, Eric, Bednar, Martin M., Brashear, H. Robert, Miller, David S., Maruff, Paul, Randolph, Christopher, Ismail, Zahinoor, Carrillo, Maria C., Weber, Christopher J., Bain, Lisa J., Hake, Ann Marie

“…Alzheimer's disease (AD) is a continuum consisting of a preclinical stage that occurs decades before symptoms appear. As researchers make advances in…”
Get full text

Predictors of progression from mild cognitive impairment to dementia in the placebo-arm of a clinical trial population by Prins, Niels D, van der Flier, Wiesje M, Brashear, H Robert, Knol, Dirk L, van de Pol, Laura A, Barkhof, Frederik, Scheltens, Philip

“…We studied the predictive value of cognitive performance, vascular risk factors, apolipoprotein E (APOE) genotype, and structural brain changes on MRI, on…”
Get more information

Effect of Carisbamate on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Participants by Gonzalez, Martha, Zannikos, Peter, DiBernardo, Allitia, Brashear, H. Robert, Ariyawansa, Jay

“…Carisbamate’s effect (200 mg twice-daily [study 1], 600 mg twice-daily [study 2]) on warfarin’s (25 mg single dose) pharmacokinetics and pharmacodynamics…”
Get full text

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial by Sperling, Reisa, Henley, David, Aisen, Paul S, Raman, Rema, Donohue, Michael C, Ernstrom, Karin, Rafii, Michael S, Streffer, Johannes, Shi, Yingqi, Karcher, Keith, Raghavan, Nandini, Tymofyeyev, Yevgen, Bogert, Jennifer, Brashear, H Robert, Novak, Gerald, Thipphawong, John, Saad, Ziad S, Kolb, Hartmuth, Rofael, Hany, Sanga, Panna, Romano, Gary

“…Atabecestat, a nonselective oral β-secretase inhibitor, was evaluated in the EARLY trial for slowing cognitive decline in participants with preclinical…”
Get more information

Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics and Safety of Carisbamate by Moore, Kenneth, Zannikos, Peter, Solanki, Bhavna, Greenspan, Andrew, Verhaeghe, Tom, Brashear, H. Robert

“…This open-label, parallel-group study was designed to characterize the pharmacokinetics (PK) of carisbamate in participants with mild or moderate hepatic…”
Get full text

The Discovery of Anti-Yo (Anti-PCA1) Antibody in Patients with Paraneoplastic Cerebellar Degeneration: Opening a Window into Autoimmune Neurological Disease by Greenlee, John E., Brashear, H. Robert

“…Prior to 1982, ovarian and certain other cancers were known to have a rare complication of progressive cerebellar ataxia, a disorder characterized…”
Get full text

Comment: Age effects on clinical trial results in Alzheimer dementia by Brashear, H Robert

“…Therapeutic trials in Alzheimer disease (AD) are notoriously difficult and have produced no new approved treatments in the past decade.1 Trial success often…”
Get full text

Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients by Ketter, Nzeera, Brashear, H Robert, Bogert, Jennifer, Di, Jianing, Miaux, Yves, Gass, Achim, Purcell, Derk D, Barkhof, Frederik, Arrighi, H Michael

“…Amyloid-related imaging abnormalities (ARIA) consist of ARIA-E (with effusion or edema) and ARIA-H (hemosiderin deposits [HDs]). To address accurate…”
Get more information

Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis by Arrighi, H Michael, Barakos, Jerome, Barkhof, Frederik, Tampieri, Donatella, Jack, Clifford, Melançon, Denis, Morris, Kristen, Ketter, Nzeera, Liu, Enchi, Brashear, H Robert

“…BackgroundAmyloid-related imaging abnormalities due to haemosiderin deposition (ARIA-H) occur in patients with mild to moderate dementia due to Alzheimer's…”
Get full text

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Bapineuzumab: A Single‐Ascending‐Dose Study in Patients With Mild to Moderate Alzheimer Disease by Lu, Ming, Brashear, H. Robert

“…This study was designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending subcutaneous doses of bapineuzumab in…”
Get full text

Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease by Novak, Gerald, Fox, Nick, Clegg, Shona, Nielsen, Casper, Einstein, Steven, Lu, Yuan, Tudor, Iulia Cristina, Gregg, Keith, Di, Jianing, Collins, Peter, Wyman, Bradley T, Yuen, Eric, Grundman, Michael, Brashear, H Robert, Liu, Enchi

“…Bapineuzumab, an anti-amyloid-β monoclonal antibody, was evaluated in two placebo-controlled trials in APOE*ɛ4 carriers and noncarriers, respectively, with…”
Get more information

Pharmacokinetics of extended-release and immediate-release formulations of galantamine at steady state in healthy volunteers by Zhao, Qinying, Janssens, Luc, Verhaeghe, Tom, Robert Brashear, H., Truyen, Luc

“…ABSTRACT Objective: To assess the steady-state galantamine (GAL) bioavailability of the extended-release 24‐mg qd capsule (GAL‐ER) with and without food and to…”
Get full text

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease by Brody, Mark, Liu, Enchi, Di, Jianing, Lu, Ming, Margolin, Richard A, Werth, John L, Booth, Kevin, Shadman, Anna, Brashear, H Robert, Novak, Gerald

“…Bapineuzumab, a humanized monoclonal antibody, targets amyloid-β (Aβ1-40/1 -42) that is believed to play a key role in the pathogenesis of Alzheimer disease…”
Get more information

Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease by Carrillo, Maria C, Brashear, H. Robert, Logovinsky, Veronika, Ryan, J. Michael, Feldman, Howard H, Siemers, Eric R, Abushakra, Susan, Hartley, Dean M, Petersen, Ronald C, Khachaturian, Ara S, Sperling, Reisa A

“…Abstract Current research including the basic biology of Alzheimer's disease (AD) provides a foundation to explore whether our current state of knowledge is…”
Get full text